ARWR — Arrowhead Pharmaceuticals Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $42.99
- YTD price return
- -35.25%
- YTD total return
- -35.25%
- Market cap
- 6.1B
- Enterprise value
- 5.4B
- Shares outstanding
- 141.4M
- 52W low
- $37.06
- 52W high
- $95.49
- From 52W high
- -54.98%
- From 52W low
- +16.00%
- 52W range
- 10%$37.06–$95.49
- Beta
- 1.27
Volume
- Rel volume
- 1.77×
- 30D volume
- 2.1M
- 30D $ vol
- 114.4M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- none
- Insider net 1Y
- −$10.3M
Form 4 transactions by trade date, as filed; latest on file 2026-08-18.
Fundamentals
- Sales (ttm)
- 450.8M
- Sales/share
- $3.19
- EPS (ttm)
- -$5.11
- FCF (ttm)
- -283.9M
- FCF/share
- -$2.01
- Book value/share
- $0.36
- Net margin
- -160.64%
- ROE
- -1439.40%
- ROA
- -41.66%
- Debt / equity
- 16.67×
- Current ratio
- 4.14
Growth (CAGR, ttm) · 10Y
- Sales
- -45.67%+23.25%+26.67%+121.56%
- Shares
- +4.10%+9.58%+6.23%+6.66%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- -47.81%+12.48%+19.24%+107.72%
- Book value/share
- -89.64%-47.95%-38.09%-12.07%
- Price
- +7.08%+15.28%-7.58%+25.48%
- Total return
- +7.08%+15.28%-7.58%+25.48%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -8.4×
- Fwd P/E
- -14.7×
- P/S (ttm)
- 13.5×
- P/B (mrq)
- 120.8×
- EV/Sales (ttm)
- 12.0×
- FCF yield (ttm)
- -4.67%
- Buyback yield (realized, 1y)
- -4.10%
- Shareholder yield (realized, 1y)
- -4.10%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 26th
- P/B
- 99th
Bar = where today’s multiple sits in ARWR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m10Y n/mYoY n/mFY26: operating cash flow −$271.9M, capex −$12M
Q4 2026: operating cash flow −$192.4M, capex −$3.4M
Shares (diluted)
5Y +36.5%5Y +36.5%YoY +5.6%Net income
5Y n/m10Y n/mYoY n/mAbout Arrowhead Pharmaceuticals#
Data provided bySource: Twelve DataArrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.
Pasadena, CA·711 employees·Biotechnology·arrowheadpharma.com·As of Oct 28, 2026
Recent filings#
- Nov 12Earnings · Earnings release — EPS −$3.04 vs −$1.59 est. (−91.2%); revenue $37.8M (−85% y/y) 1.3%
- Nov 48-K · Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
- Aug 18Insider sale · PERRY MICHAEL S (Director) sold 11,600 shares for $1.0M at $87.30
- Aug 18Insider sale · OLUKOTUN ADEOYE Y (Director) sold 2,000 shares for $174K at $86.96
- Aug 4Earnings · Earnings release — EPS −$1.36 vs −$1.23 est. (−10.6%); revenue $75.3M (+171% y/y) 3.0%
ETFs holding ARWR#
24 of the 193 ETFs ChartRow carries live hold ARWR. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| XBI | SPDR S&P Biotech ETF | 1.1% |
| IBB | iShares Biotechnology ETF | 0.8% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.3% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.3% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.2% |
| VHT | Vanguard Health Care ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
